and the Transfusion Safety Study Group. Effect of low- and intermediate-purity clotting factor therapy on progression of human immunodeficiency virus infection in congenital clotting disorders - Gjerset, G F; Pike, M C; Mosley, J W; Hassett, J; Fleteher, M A; Donegan, E; Parker, J W; Counts, R B; Zhou, Y; Kasper, C K; Operskalski, E A (Blood, 1994)